Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #16 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Gland Pharma Limited (this stock) | 48,028 | 34.4 | 9.9% | 50.1% | 0.69% | 66 | 37 | 50 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 1,800 | 435 | 317 | ₹ |
| March 31, 2026 | 1,743 | 506 | 367 | ₹ |
| Dec. 31, 2025 | 1,695 | 362 | 261 | ₹ |
| Sept. 30, 2025 | 1,487 | 284 | 184 | ₹ |
| June 30, 2025 | 1,506 | 313 | 215 | ₹ |
| March 31, 2025 | 1,425 | 288 | 187 | ₹ |
| Dec. 31, 2024 | 1,384 | 299 | 205 | ₹ |
| Sept. 30, 2024 | 1,406 | 257 | 164 | ₹ |
| June 30, 2024 | 1,402 | 218 | 144 | ₹ |
| March 31, 2024 | 1,537 | 298 | 192 | ₹ |
| Dec. 31, 2023 | 1,545 | 283 | 192 | ₹ |
| Sept. 30, 2023 | 1,373 | 290 | 194 | ₹ |
| June 30, 2023 | 1,209 | 261 | 194 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 6,431 | 1,465 | 1,027 |
| March 31, 2025 | 5,617 | 1,063 | 699 |
| March 31, 2024 | 5,665 | 1,133 | 772 |
| March 31, 2023 | 3,625 | 1,055 | 781 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 1,031 | 138 | -417 | 491 | 541 |
| March 31, 2025 | 915 | 1,705 | -433 | 385 | 530 |
| March 31, 2024 | 997 | -1,757 | -799 | 390 | 607 |
| March 31, 2023 | 364 | 1,208 | 15 | 221 | 143 |
| March 31, 2022 | 791 | -1,003 | 35 | 511 | 279 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 12,511 | 10,358 | 10,341 | 173 | 70 | 7,527 | 1,608 | 3,359 | 4,052 | 1,744 |
| March 31, 2025 | 11,225 | 9,151 | 9,134 | 192 | 78 | 6,783 | 1,565 | 2,556 | 3,751 | 1,685 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
